KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Intangibles: 2011-2025

Historic Intangibles for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $623.5 million.

  • Supernus Pharmaceuticals' Intangibles rose 15.43% to $623.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $623.5 million, marking a year-over-year increase of 15.43%. This contributed to the annual value of $521.9 million for FY2024, which is 13.00% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Intangibles stood at $623.5 million for Q3 2025, which was up 29.54% from $481.3 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Intangibles high stood at $784.7 million for Q4 2021, and its period low was $346.6 million during Q3 2021.
  • In the last 3 years, Supernus Pharmaceuticals' Intangibles had a median value of $579.8 million in 2024 and averaged $581.3 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Intangibles skyrocketed by 1,421.42% in 2021 and then fell by 15.75% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Intangibles (Quarterly) stood at $784.7 million in 2021, then declined by 10.48% to $702.5 million in 2022, then fell by 14.60% to $599.9 million in 2023, then decreased by 13.00% to $521.9 million in 2024, then climbed by 15.43% to $623.5 million in 2025.
  • Its last three reported values are $623.5 million in Q3 2025, $481.3 million for Q2 2025, and $502.1 million during Q1 2025.